Scott D. Sandell

October 17, 2026

Cloudflare stock slides as market rises, AI security demo. Cloudflare's stock recently declined while the broader market rose, reflecting a pullback in software sector sentiment. On the business side, the company joined Google, GoDaddy, and Infoblox to demonstrate secure AI agent transactions across platforms. The stock is currently trading within its 52-week range of $158.83 to $370.35, below the average analyst target of $343.42.

October 15, 2026

Coursera Faces Hold Rating, Q3 Outlook Uncertain Amid AI Growth. Coursera was downgraded to Hold ahead of its Q3 earnings, as analysts await progress on a potential merger. A preview of the quarter suggests the stock could be a value trap until organic growth resumes. The company is also part of the AI retraining boom, but its price remains near the $5.30 support level.

October 6, 2026

Korro Bio Begins Phase 1/2 Trial for KRRO-121. Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.

September 7, 2026

SpyGlass Pharma Schedules Upcoming Investor Conference Participation. SpyGlass Pharma has announced its participation in upcoming investor conferences, a routine corporate engagement where company leadership typically meets with institutional investors and analysts to discuss business performance and outlook. The stock is currently trading near the upper end of its 52-week range of $17.06 to $32.44, with the average analyst price target standing at $44.00 based on six analyst estimates. Technical indicators show elevated momentum readings alongside a recent Bollinger band breakout, reflecting recent market interest in the pharmaceutical company's shares.

October 16, 2026

MBX Biosciences to Attend Investor Conferences, Analyst Target Raised. MBX Biosciences will join several investor conferences in November, offering a chance for investors to hear about its pipeline. Stifel has kept a positive stance and lifted its target price to $84. Analysts are debating whether the recent 257% jump has pushed the stock above fair value, while others question if the pullback from a strong year run still leaves room for upside.

September 25, 2026

Goldman Sachs reinstates Sell rating on SGMT with $7 target. Goldman Sachs has reinstated a Sell rating on Sagimet Biosciences, setting a price target of $7. This move stands in contrast to the average analyst target of $29.60, highlighting a significant divergence in expert opinions. The stock is currently trading near its 52-week low of $4.50, reflecting the bearish sentiment associated with the new rating.

October 7, 2026

Savara Stock Mentioned Among Gainers in Market Roundup. Savara Inc. was included in a recent market roundup highlighting stocks that moved higher on Wednesday. The company's shares are currently trading near a key support level, which may have contributed to the short-term price movement noted in the report. This mention reflects general market activity rather than a specific corporate announcement.

October 8, 2026

Mirum Pharma's Brevlovitug Hits Phase III Endpoint in Hepatitis Delta. Mirum Pharmaceuticals announced that its drug Brevlovitug met the primary endpoint in a Phase III study for hepatitis delta. The result supports the drug’s potential to become a treatment option for a rare viral infection. The news may influence how investors view the company’s pipeline and future growth prospects.

October 16, 2026

CBIO Announces New Clinical Trial Milestones for CR-001. Crescent Biopharma said it is enrolling patients in the standard‑of‑care chemotherapy arms of its global Phase 1/2 ASCEND trial for CR‑001, a PD‑1 × VEGF bispecific antibody. The company also began additional antibody‑drug‑conjugate combination studies with CR‑001. These steps indicate progress in the drug’s development and broaden its potential clinical applications.

October 4, 2026

IonQ: Quantum Sector Momentum vs. Fundamentals Debate. Recent coverage focuses on whether the quantum computing rally is driven by real progress or just market momentum. Articles compare IonQ to peers like Rigetti and Alphabet, highlighting how AI and supercomputing integration may give IonQ an edge. While the stock has seen recent gains, analysts continue to debate if current valuations match the company's fundamental growth.

October 17, 2026

Wolfe downgrade and CEO stock sale weigh on Robinhood. Robinhood shares fell nearly 9% following a downgrade from Wolfe, a move attributed to shrinking valuation concerns. The stock also faced attention after the CEO sold $43 million in shares, a transaction described as not being what it seems. Implied volatility for Robinhood options is surging, reflecting heightened uncertainty around the stock's future direction.

October 12, 2026

TRVI releases Q2 2026 earnings and makes Raymond James top health list. Trevi Therapeutics held its Q2 2026 earnings call, sharing the latest financial and operational results. In a separate note, Raymond James analysts listed the stock among their top four healthcare picks. The earnings discussion and analyst endorsement may draw additional attention to the company. The shares are trading close to the upper end of their 52‑week range.

October 17, 2026

Bloom Energy shares up 157% in 2026 as analysts debate valuation. Bloom Energy stock has risen 157% in 2026, prompting discussion on whether investors should take profits. Truist Securities recently raised its price target to $240 while maintaining a Hold rating. With the stock trading near its 52-week low relative to its recent peak, analysts are watching if the company can repeat its previous quarter's strong revenue performance.

October 15, 2026

Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.